L. Sivcheva

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups

K. Krejcy, C. Klade, R. Kralovics, 2020, HemaSphere.

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

K. Krejcy, C. Klade, R. Kralovics, 2022, Leukemia.

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.

K. Krejcy, C. Klade, R. Kralovics, 2020, The Lancet. Haematology.

Evidence for Superior Efficacy and Disease Modification after Three Years of Prospective Randomized Controlled Treatment of Polycythemia Vera Patients with Ropeginterferon Alfa-2b Vs. HU/BAT

K. Krejcy, C. Klade, R. Kralovics, 2018, Blood.

Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV)

K. Krejcy, C. Klade, R. Kralovics, 2022, Blood.

Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension

K. Krejcy, C. Klade, R. Kralovics, 2020 .